From: Fatigue and quality-of-life in the year following SARS-Cov2 infection
M6 n = 120 |
M12 n = 120 | |
---|---|---|
Re-hospitalisation | ||
Yes (%) | 4 (3.33) | 10 (8.33) |
Experienced dyspnoea | ||
Yes (%) | 47 (39.87) | 50 (41.67) |
Experienced palpitations | ||
Yes (%) | 19 (15.83) | 19 (15.83) |
Chest pains | ||
Yes (%) | 19 (15.83) | 18 (15) |
Cough | ||
Yes (%) | 24 (20.17) | 25 (20.83) |
Headaches | ||
Yes (%) | 24 (20.17) | 25 (20.83) |
Arthromyalgia | ||
Yes (%) | 49 (41.88) | 56 (46.67) |
Diarrhoea | ||
Yes (%) | 19 (16.24) | 20 (16.67) |
Other symptoms* | ||
Yes (%) | 42 (35.00) | 54 (45.00) |
Systolic blood pressure | ||
Median [Q1–Q3] | 132.00 [120.00–145.0] | 133.00 [120.00–149.00] |
≤ 140 mmHg (%) | 77 (65.81) | 71 (61.21) |
> 140 mmHg (%) (high blood pressure) | 40 (34.19) | 45 (38.79) |
Heart rate (bpm) | ||
Median [Q1–Q3] | 76.00 [67.00–88.00] | 78.00 [66.00–85.00] |
mMRC rating | ||
0 (%) | 45 (37.50) | 42 (35.59) |
1 (%) | 37 (30.83) | 36 (30.51) |
2 (%) | 17 (14.17) | 19 (16.10) |
3 (%) | 12 (10.00) | 12 (10.17) |
4 (%) | 9 (7.50) | 9 (7.63) |
Anxiolytics | ||
Yes (%) | 11 (9.32) | 15 (12.50) |
BMI | ||
Median [Q1–Q3] | 28.00 [25.00–32.00] | 28.00 [25.00–32.00] |
≥ 40 kg/m2 (%) | 9 (7.56) | 7 (5.83) |
< 40 kg/m2 (%) | 110 (92.44) | 113 (94.17) |
SpO2 | ||
Median [Q1–Q3] | 97.00 [96.00–98.00] | 96.00 [94.00–97.75] |
< 94% (%) | 2 (1.74) | 6 (5.26) |
> 94% (%) | 113 (98.26) | 108 (94.74) |
Hypnotics | ||
Yes (%) | 7 (5.93) | 15 (12.5) |
Antidepressants | ||
Yes (%) | 11 (9.32) | 17 (14.17) |
Anticoagulants | ||
Yes (%) | 19 (16.10) | 18 (15.00) |
Asthenia | ||
Yes (%) | 69 (57.50) | 69 (57.50) |
FSS mean score | ||
> 4 (%) | 39 (35.65) | 51 (43.97) |
< 4 (%) | 72 (64.35) | 65 (56.03) |
Mean ± SD | 3.42 ± 1.87 | 3.60 ± 1.97 |
SF12 score | ||
PCS12: mean ± SD | 42.85 ± 10.03 | 42.18 ± 9.60 |
MCS12: mean ± SD | 46.70 ± 7.57 | 47.13 ± 6.43 |